Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

Final draft guidance

Final appraisal document (PDF 320 KB)

Committee papers (PDF 2.25 MB)

Public committee slides (Committee meeting 6) (PDF 580 KB)

Draft guidance: 3

Appraisal consultation document (PDF 366 KB)

Committee papers (PDF 3.61 MB)

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): appraisal consultation

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): appraisal consultation document information

Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): evaluation report information

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): Evaluation report information

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): final scope

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): final matrix

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): equality impact assessment - scoping

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): response to consultee and commentator comments on the draft scope and provisional matrix (post-referral)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): draft scope (post-referral)

Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): provisional matrix (post-referral)